Riskpilot← Back to searchSign inGet full accessZADEC ApS
APSActiveCVR 29312206Agern Alle 24-26Research and experimental development on natural sciences and engineering · NACE 7210Est. 2006— employees
Revenue 2024
DKK -85K
-43% vs 2023
EBITDA margin
100.0%
+43% vs 2023
Equity ratio
-533.1%
Financial strength
Net profit 2024
DKK -309K
+13% vs 2023
| Revenue | DKK -85K | -43% |
| EBITDA | DKK -85K | +43% |
| Net profit | DKK -309K | +13% |
| Total assets | DKK 437K | +1% |
| Equity | DKK -2,3M | -15% |
| Employees | — | — |
Legal name
ZADEC ApS
CVR number
29312206
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23. januar 2006
Share capital
DKK 500.021
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren.
Company purpose
Selskabets formål er at drive handel, forskning og udvikling.
Address
Agern Alle 24-26
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -2.654 | -2.615 | -1.236 | -2.247 | -1.793 | -551 | -368 | -235 | -231 | -224 | -205 | -150 | -85 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -2.654 | -2.615 | -1.236 | -2.247 | -1.793 | -551 | -368 | -235 | -231 | -224 | -205 | -150 | -85 |
| Depreciation & amort. | -56 | -19 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2.709 | -2.633 | -1.236 | -2.247 | -1.793 | -551 | -368 | -235 | -231 | -224 | -205 | -150 | -85 |
| Net financials | -4.853 | -5.212 | -5.798 | -10.091 | -837 | -133 | -37 | -49 | -63 | -49 | -44 | -204 | -224 |
| Profit before tax | -7.562 | -7.845 | -7.033 | -12.338 | -2.630 | -684 | -405 | -284 | -294 | -273 | -249 | -355 | -309 |
| Tax | -41 | 35 | -33 | -2.002 | 1.331 | -466 | -89 | -63 | 63 | -0 | -0 | -0 | -0 |
| Net profit | -7.521 | -7.880 | -7.000 | -10.336 | -3.961 | -218 | -316 | -222 | -356 | -273 | -249 | -355 | -309 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 371 | 700 | 331 | 5.005 | 18.001 | 583 | 348 | 512 | 564 | 487 | 477 | 434 | 437 |
| Equity | -105.182 | -113.062 | -120.062 | 3.927 | -34 | -252 | -568 | -790 | -1.146 | -1.419 | -1.668 | -2.022 | -2.331 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 105.552 | 113.762 | 120.393 | 1.078 | 18.035 | 835 | 916 | 1.302 | 1.710 | 1.906 | 2.145 | 2.456 | 2.768 |
| Total debt | 105.552 | 113.762 | 120.393 | 1.078 | 18.035 | 835 | 916 | 1.302 | 1.710 | 1.906 | 2.145 | 2.456 | 2.768 |
EBITDA margin
-8498800.0%
This company
15.8%
Market median
-53789973% vs market
20122024
Equity ratio
-533.1%
This company
38.2%
Market median
-1496% vs market
20122024
Return on equity
-30878600.0%
This company
18.4%
Market median
-167818578% vs market
20122024
Net profit margin
-30878600.0%
This company
8.1%
Market median
-381217384% vs market
20122024
Asset turnover
-0.19×
This company
1.12×
Market median
-117% vs market
20122024
Debt / equity
1.19×
This company
0.62×
Market median
-92% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TA Management | Management | 2025 | — | — |
AM Management | Management | 2006 | — | — |
JJ Founder | Founder | 2006 | — | — |
SS Management | Management | 2006 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
MC2 Therapeutics A/S | Company | 90.0% | 90.0% | 2011 |
FEY HOLDING ApS | Company | 5.0% | 5.0% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FEY HOLDING ApS
ZADEC ApS Board members of ZADEC ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Trine Ahlgreen | Management | 0 companies |
| Anette Merete Nøhr Clausen | Management | 0 companies |
| Jesper Jørn Lange | Founder | 0 companies |
| Steen Sindet-Pedersen | Management | 0 companies |